# Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

> **NCT07510724** · — · RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 240 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- Non-Small Cell Lung Cancer (NSCLC)
- Lung Cancer (Diagnosis)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07510724
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2032-12-23
- **Final completion:** 2033-01-23
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510724, "Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07510724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*